Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1911-1914

  Miyazaki, Mitsuru ^a   Oguri, Tetsuya ^a   Kurata, Takayasu ^a   Takahashi, Toshiaki ^a   Daga, Haruko ^a   Fujitaka, Kazunori ^a   Isobe, Takeshi ^a   Nakajima, Masamitsu ^a   Fujiwara, Yasuhiro ^a   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

AUC; Carboplatin; Limited sampling model; Taxane

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; ONDANSETRON; PACLITAXEL; TAXANE DERIVATIVE;

ACCURACY; ADENOCARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SAMPLING; VALIDATION PROCESS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; REPRODUCIBILITY OF RESULTS; TAXOIDS;

EID: 3242706113     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Duffull SB and Bobinson BA: Clinical pharmacokinetics and dose optimization of carboplatin. Clin Pharmacokinet 33: 161-183, 1997.
2. Miyazaki M, Fujiwara Y, Takahashi T, Isobe T, Ohune T, Tsuya T and Yamakido M: Limited-sampling models for estimation of the carboplatin area under the curve. Anticancer Res 17: 4571-4576, 1997.
3. Belani CP: Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest 117(4 Suppl 1): 144S-151S, 2000.
4. Warmerdam LJC van, Ten Bokkel Huinink WW, Maes RAA and Beijnen JH: Limited sampling models for anticancer agents. J Cancer Res Clin Oncol 120: 427-433, 1994.
5. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Alilshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
6. Fujiwara Y, Takahashi T, Yamakido M, Ohune T, Tsuya T and Egorin MJ: Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 89: 260-261, 1997.
7. LeRoy AF, Wehling ML, Sposeller HL, Friauf WS, Solomon RE and Dedrick RL: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184-191, 1977.
8. Yamaoka K, Nakagawa T and Uno T: Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 223-252, 1987.
9. Sheiner LB and Beal SL: Scientific commentary. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-512, 1981.
10. Kivisto K, Kroemer HK and Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40: 523-530, 1995.
11. Rahman A, Korozewa KR, Grogan J, Gonzalez FJ and Harris JW: Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54: 5543-5546, 1994.
12. Royer I, Monsarrat B, Sonnier M, Wright M and Cresteil T: Metabolism of docetaxel by human cytochrome P450: Interaction with paclitaxel and other antineoplastic drugs. Cancer Res 56: 58-65, 1996.
13. Oguri T, Fujiwara Y, Miyazaki M, Takahashi T, Kurata T, Yokozaki M, Ohashi N, Isobe T, Katoh O and Yamakido M: Induction of γ-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients. Ann Oncol 10: 455-460, 1999.
14. Huizing M, Giaccone G, van Warmerdan LJC, Rosing H, Bakker PJM, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MGJ, ten Bokkel Huinink WW, van der Vijgh WJF, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CHN and Beijnen JH: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 15: 317-329, 1997.
15. Fujiwara K, Yamauchi H, Suzuki S, Ishikawa H, Tanaka Y, Fujiwara M and Kohno I: The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol 47: 22-26, 2001.
16. Nannan Panday VR, van Warmerdam LJC, Huizing MT, Ten Bokkel Huinink WW, Schellens JHM and Beijnen JH: A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. J Cancer Res Clin Oncol 125: 615-620, 1999.